中国实用内科杂志2024，Vol.44Issue(9)：734-739,6.DOI:10.19538/j.nk2024090103
2024年版KDIGO《ANCA相关性血管炎管理临床实践指南》更新重点内容解读
Interpretation of updated key content of 2024 KDIGO Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis
摘要
Abstract
The most significant updates in 2024 version of"KDIGO Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis"are related to induction therapy.Avacopan,an oral C5a receptor antagonist,is an effective substitute for glucocorticoids in the treatment of ANCA-associated AAV,and may improve renal outcomes.For patients with AAV overlapped with anti-glomerularbasementmembrane(GBM)disease,plasma exchange therapy is required.Maintenance therapy is not changed in this guideline updates;for rituximab,the updated guidelines now mention that the optimal duration of treatment is 18 months to 4 years after induction of remission,and rituximab can be measured based on a fixed schedule or the reemergence of CD19+B cells and/or ANCA.There is no change in this guidelines concerning the content of AAV patients with relapsing or refractory disease or those after kidney transplantation.关键词
抗中性粒细胞胞浆抗体相关血管炎/改善全球肾脏病预后组织/临床实践指南/解读Key words
anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis/Kidney Disease:Improving Global Outcomes(KDIGO)/clinical practice guideline/interpretation分类
医药卫生引用本文复制引用
徐莹,韩飞..2024年版KDIGO《ANCA相关性血管炎管理临床实践指南》更新重点内容解读[J].中国实用内科杂志,2024,44(9):734-739,6.基金项目
浙江省重点研发计划项目(2020C03034) （2020C03034）
浙江省自然科学基金探索项目(LY20H050001) （LY20H050001）
